Clinical Trial Update: CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia [EARLY_Phase 1]

View source ↗

Summary

This early-phase clinical trial update describes sequential infusion of CD123+CLL-1 CAR-T cells with a CD7 CAR-T and bridging to allogeneic stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD123+CLL-1 CAR-T (CD123 CAR-T and CLL-1 CAR-T)
• CD7 CAR-T (CD7-directed chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML - Acute Myeloid Leukemia | EARLY_Phase 1 | Status: NOT_YET_RECRUITING